Gene
OR1D2
| Entrez Gene ID | 4991 (See on NCBI) |
| Description | olfactory receptor, family 1, subfamily D, member 2 |
| Gene Synonyms | OLFR1, OR17-4 |
| Node consisting of this Gene | OR1G1///OR1E3///OR1D2 OR1D2 |
Networks including this gene
| GSE10063_top8000 - GSE10063 - SiGN-BN NNSR | Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia |
| GSE10972_top8000 - GSE10972 - SiGN-BN NNSR | Colon cancer |
| GSE11121_top8000 - GSE11121 - SiGN-BN NNSR | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE11869_top8000 - GSE11869 - SiGN-BN NNSR | The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. |
| GSE12093_top8000 - GSE12093 - SiGN-BN NNSR | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE12622_top8000 - GSE12622 - SiGN-BN NNSR | Tumor-associated stroma derived from primary clinical breast cancer samples (II) |
| GSE12627_top8000 - GSE12627 - SiGN-BN NNSR | Non-supervised hierarchical clustering of gene expression data |
| GSE13009_top8000 - GSE13009 - SiGN-BN NNSR | MCF7 EGF, HRG stimulation |
| GSE14764_top8000 - GSE14764 - SiGN-BN NNSR | A Prognostic Gene Expression Index in Ovarian Cancer |
| GSE14925_top8000 - GSE14925 - SiGN-BN NNSR | Expression data from Non small cell lung cancer cell lines |
| GSE15212_top8000 - GSE15212 - SiGN-BN NNSR | Identification and validation of NOL5A and RPS2 as potential therapeutic targtes in colorectal cancer |
| GSE15471_top8000 - GSE15471 - SiGN-BN NNSR | Whole-Tissue Gene Expression Study of Pancreatic Ductal Adenocarcinoma |
| GSE15641_top8000 - GSE15641 - SiGN-BN NNSR | Gene signatures of progression and metastasis in renal cell cancer |
| GSE15966_top8000 - GSE15966 - SiGN-BN NNSR | Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST) |
| GSE16237_top8000 - GSE16237 - SiGN-BN NNSR | Expression data of human neuroblastoma tissue samples |
| GSE16515_top8000 - GSE16515 - SiGN-BN NNSR | Expression data from Mayo Clinic Pancreatic Tumor and Normal samples |
| GSE17705_top8000 - GSE17705 - SiGN-BN NNSR | Endocrine Sensitivity Index Validation Dataset |
| GSE19027_top8000 - GSE19027 - SiGN-BN NNSR | Antioxidant response gene expression in the bronchial airway epithelial cells of smokers at risk for lung cancer |
| GSE19417_top8000 - GSE19417 - SiGN-BN NNSR | Human esophageal adenocarcinomas |
| GSE20189_top8000 - GSE20189 - SiGN-BN NNSR | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
| GSE20271_top8000 - GSE20271 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE22153_top8000 - GSE22153 - SiGN-BN NNSR | Gene Experssion Profiling-Based Identification of Molecular Subtypes in Stage IV Melanoma with Different Clinical Outcome (test set) |
| GSE2294_top8000 - GSE2294 - SiGN-BN NNSR | A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor-Positive Tumors |
| GSE23878_top8000 - GSE23878 - SiGN-BN NNSR | Genome Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy |
| GSE23991_top8000 - GSE23991 - SiGN-BN NNSR | Effect of zebularine on primary human liver cancer cell lines |
| GSE25136_top8000 - GSE25136 - SiGN-BN NNSR | Optimizing molecular signatures for prostate cancer recurrence |
| GSE2549_top8000 - GSE2549 - SiGN-BN NNSR | Malignant pleural mesothelioma |
| GSE26712_top8000 - GSE26712 - SiGN-BN NNSR | A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
| GSE2841_top8000 - GSE2841 - SiGN-BN NNSR | Expression Profiling of pheochromocytomas of various genetic origins |
| GSE29598_top8000 - GSE29598 - SiGN-BN NNSR | A Methodology for Utilization of Predictive Genomic Signatures in FFPE Samples |
| GSE31519_top8000 - GSE31519 - SiGN-BN NNSR | A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer |
| GSE3167_top8000 - GSE3167 - SiGN-BN NNSR | Classification of carcinoma in situ lesions in human bladder cancer |
| GSE32269_top8000 - GSE32269 - SiGN-BN NNSR | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE3726_top8000 - GSE3726 - SiGN-BN NNSR | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE4115_top8000 - GSE4115 - SiGN-BN NNSR | Airway Epithelial Gene Expression Diagnostic for the Evaluation of Smokers with Suspect Lung Cancer |
| GSE4122_top8000 - GSE4122 - SiGN-BN NNSR | Gene Expression Analysis of Ovarian Samples |
| GSE5851_top8000 - GSE5851 - SiGN-BN NNSR | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE5900_top8000 - GSE5900 - SiGN-BN NNSR | Gene Expression of Bone Marrow Plasma Cells from Healthy Donors (N=22), MGUS (N=44), and Smoldering Myeloma (N=12) |
| GSE6462_top8000 - GSE6462 - SiGN-BN NNSR | MCF7 dose response |
| GSE6481_top8000 - GSE6481 - SiGN-BN NNSR | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE6956_top8000 - GSE6956 - SiGN-BN NNSR | Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men |
| GSE7390_top8000 - GSE7390 - SiGN-BN NNSR | Strong Time Dependence of the 76-Gene Prognostic Signature |
| GSE8139_top8000 - GSE8139 - SiGN-BN NNSR | Expression data from MCF7/HER2-18 xenografts |
| GSE8141_top8000 - GSE8141 - SiGN-BN NNSR | Expression data from MCF7 wt and MCF7/HER2-18 xenografts |
| GSE8401_top8000 - GSE8401 - SiGN-BN NNSR | Gene Signature for Aggression of Melanoma Metastases - Melanoma Metastasis |
| GSE8481_top8000 - GSE8481 - SiGN-BN NNSR | Various human cell types |
| GSE8671_top8000 - GSE8671 - SiGN-BN NNSR | Transcriptome profile of human colorectal adenomas. |
| GSE9014_top8000 - GSE9014 - SiGN-BN NNSR | Tumor-associated stroma derived from primary clinical breast cancer samples |
(48 networks)
